ipopema

VIGO Photonics

Breakthrough contracts for now out of sight

Following the substantial decline in share price in 2H22, the stock has already returned to its previous levels, delivering a 25% YTD gain. Such performance was possible because the supply chain-related risk, which initiated the sell-off, is currently in our view relatively low (ca. 5% of 2023E sales at risk). Moreover, the company announced a one-time increase in product pricing of effectively ca. 20%. Nevertheless, despite expected strong y/y growth and inclusion of hikes in our forecasts, we expect VIGO to deliver 2023E revenues at PLN 96.0m (up 43% y/y, down 5% vs. prev.) and adj. net income at PLN 22.5m (vs. PLN 7.2m in 2022E, down 31% vs. prev., with the margin at 23% vs. 11% in 2022E). Our new forecasts arrive 4% below the company's revenue target and below our previous expectations, due to lower sales volumes (compensated by higher pricing), weaker than previously expected performance in the military segment (lack of a large contract from Safran), as well as weaker performance in the semiconductor sector (major orders are likely in our view on the verge of 2023E/24E). The company still possesses a strong project pipeline, but we believe a breakthrough in most cases is more likely in 2H23E+. On our 2023E/24E forecasts, VIGO trades at a P/E of 18.5x/11.2x, which we perceive as neutral for the company with solid revenue/adj. net income 2021-25E CAGR of 22%/19%, yet substantial CAPEX. We decrease our recommendation to HOLD from BUY, with a new FV of PLN 600.0 (6% upside), down from PLN 660.0.

Pricing increase is a supportive, yet one-time event

Following the weak 2022 with a revenue decline of 6% y/y (affected by a substantial decline in military), we expect the company to deliver strong 43% y/y growth to PLN 96m in 2023E. The major driver will be an increase in detector unitary prices, which we expect to be effectively 18% higher y/y this year. Considering individual segments, we forecast industry to deliver PLN 55m in revenues (up 37% y/y, without signs of a macro-driven slow-down), military at PLN 13m (up 61% y/y, driven by high investment in the Polish Army), transport at PLN 11.5m (up 48% y/y, with a potentially large EUR 2m contract starting this year) and semiconductor materials at PLN 8m (the second epitaxy machine should be operative for nearly a full year). Even though we expect substantial improvement in adjusted net margins in 2023E to 23%, (vs. 11% in 2022E and on average 33% in 2019-21) thanks to increased pricing, effects of scale and OPEX discipline, our new forecast is substantially below previous estimates of an adjusted net margin of 32%.

Breakthrough contract for now out of sight

Out of the three major projects in the R&D pipeline (IR array, biomedical sensor and IR in automotive), we believe signing a framework production contract for IR array is the most possible to happen in the coming months, whereas for the remaining two projects we expect a potential breakthrough rather in 2H23/2024E. All three contracts, if successful, are likely to effectively support results starting in 2024E/25E and we include them in our forecast, adjusted by a probability ratio (we expect VIGO's accelerated revenue growth rate at 30% y/y in 2025E to PLN 158m).

Figure 1. Summary of financial data (PLN m)

	2020	2021	2022E	2023E	2024E	2025E
Revenues	53.5	71.5	67.3	96.0	121.1	157.7
EBITDA	26.5	31.5	17.8	35.3	52.7	68.6
Norm. net income	18.1	24.4	7.2	22.5	37.2	49.7
EV/EBITDA (x)	17.4	17.5	31.2	14.9	9.5	6.8
P/E (x)	22.8	20.0	57.2	18.5	11.2	8.4
DY	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: Company, IPOPEMA Research


TMT | Technology

VIGO PHOTONICS

HOLD FV PLN 600.0 from PLN 660.0

6% upside

Price as of 27 March 2023 PLN 566.0 Downgraded from BUY



Share data

Number of shares (m)	0.7
Market cap (EUR m)	88.0
12M avg daily volume (k)	0.4
12M avg daily turnover (EUR k)	49.9
12M high/low (PLN)	738.0/401.0
WIG weight (%)	0.1
Reuters	VGOP.WA
Bloomberg	VGO PW

Total performance			
1M	+16.0%		
3M	+30.0%		
12M	-20.0%		

Shareholders

Warsaw Equity Management	14.3%
Józef Piotrowski	11.9%
TFI Investors SA	9.6%
Janusz Kubrak	6.6%
Allianz OFE	5.3%
Mirosław Grudzień	5.1%
Others	47.2%

Analyst

Michał Wojciechowski Michal.Wojciechowski@ipopema.pl + 48 22 236 92 69 This document has been prepared by IPOPEMA Securities S.A. with its registered seat in Warsaw, Próżna 9, 00-107 Warsaw, Poland, entered into the Register of Entrepreneurs of the National Court Register maintained by the District Court for the City of Warsaw, XII Commercial Division of the National Court Register under entry number KRS 0000230737, the initial capital and paid capital in the amount of PLN 2.993.783,60, NIP 5272468122, www.ipopema.pl. IPOPEMA Securities S.A. is supervised by the Polish Financial Supervision Authority (Komisja Nadzoru Finansowego), Piękna 20, 00-549 Warsaw, Poland.

This document has been prepared by IPOPEMA Securities S.A.as a part of the Warsaw Stock Exchange Research Coverage Support Program ("Program") and was commissioned by the Warsaw Stock Exchange SA ("WSE"). Information about the Program is available at https://www.gpw.pl/gpwpa. The copyright to the document is vested in the WSE. For preparation of the document, IPOPEMA Securities S.A will be remunerated by the WSE on the terms specified in the agreement concluded between IPOPEMA Securities S.A and the WSE.

This document was prepared by IPOPEMA Securities S.A. for information purposes only. This document is addressed to IPOPEMA Securities S.A. clients entitled to receive it on the basis of contracts for the provision of services. This document, using media distribution channels, may also reach other investors. It has been produced independently of the company mentioned in this document and any forecasts, opinions and expectations are entirely those of IPOPEMA Securities S.A. Unless otherwise specified, the estimates and opinions contained in the document constitute an independent assessment of IPOPEMA Securities S.A. analysts preparing the document as of the date of issuing the document.

IPOPEMA Securities S.A. prepared this document with the preservation of all adequate diligence, thoroughness and reliability on the basis of publicly available information which IPOPEMA Securities S.A. believes to be reliable. While due diligence has been taken by IPOPEMA Securities S.A. to ensure that the facts stated herein are accurate and that any forecasts, opinions and expectations contained herein are fair and reasonable, IPOPEMA Securities S.A. has not independently verified all the information given in this document. Accordingly, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this document. The opinions expressed in the document can change without notice and IPOPEMA Securities S.A. is under no obligation to keep these opinion current. None of the IPOPEMA Securities S.A. or any other person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith. This document nor any copy hereof is not to be distributed directly or indirectly in the United States, Australia, Canada or Japan.

This document does not constitute any offer to sell or induce any offer to buy or sell any financial instruments, can not be relied on in connection with any contract or liability and does not constitute advertising or promotion of a financial instrument or the company. Investment decisions should only be made on the basis of a prospectus or other publicly available information and materials.

The document was prepared without taking into account the needs and situation of the recipients of the document. When preparing the document, IPOPEMA Securities S.A. does not examine the recipient's investment objectives, risk tolerance level, time horizon and financial standing of the investors. The company or the financial instruments discussed in the document may not be suitable for the users of the document, i.e. it may not be suitable for the specific objectives and time horizon or the financial situation. Information included in the document can not be regarded as a substitute for obtaining investment advice service. The value of financial instruments may fluctuate, including declines. Changes in FX rates may have an adverse effect on the value of investments. The investment in financial instruments is linked to investment risks including loss of entire or part of the invested capital. Past performance is not necessarily indicative of future results. IPOPEMA Securities S.A. points out that the price of financial instruments is affected by many different factors that are or may be independent of the company and the results of its operations. These include, among others changing economic, legal, political and tax conditions.

Investors should be aware that IPOPEMA Securities S.A. or its related entities may have a conflict of interest that could affect this document's objectivity. The investor should assume that IPOPEMA Securities S.A. or its related entities may provide services in favour of the company and obtain remuneration on this account. They may also have another financial interest with respect to the company. IPOPEMA Securities S.A. or its related entities may seek to do business with the company or other entities mentioned in this document. IPOPEMA Securities S.A. has an organizational structure and internal regulations in place to ensure that the client's interests are not compromised in the event of a conflict of interests, in relation to preparing this document. This document was prepared irrespective and independently of the interests of IPOPEMA Securities S.A., the company that is the subject of this document and holder of financial instrument issued by aforementioned company.

IPOPEMA Securities S.A. uses a number of valuation methodologies including discounted cash flows models (such as discounted operating earnings or dividend discount model), and earnings and cash-flow based models, which are often related to comparisons with selected peer companies. Cash flow models encapsulate the cash streams forecast to flow to a company, and are widely used in the investment industry. Peer comparisons factor in amongst other factors, differential growth rates, and indicate how expensive one company might appear relative to a chosen comparator. The subjective opinions of the document's author or authors, formed by their knowledge and experience, play a significant role in the valuation. Also included are assumptions on numerous economic variables, particularly interest rates, inflation and exchange rates and varying these assumptions could results in significantly different opinions. The strength of the earnings and cash flow based models is the closer attention to a company on a standalone basis, and tying the valuation to its fundamental value. The weakness of such method is the number of assumptions, which need to be adopted and resulting sensitivity to those assumptions. The peer comparisons methods are less dependent on the analyst's judgment as to the individual parameters, however the problem with this method appears when the peer comparisons is over- or undervalued. Moreover, leading multiples (based on the future earnings, book values, operating profit or cash flows) include an analyst's estimate of those values.

This document was not transferred to the company prior to its publication. This document was prepared according to the author's own view, assumptions and knowledge.

It is intended that the analytical report concerning the company will be updated at least twice a year starting from the date of publication of the initiating report, and in the event of key operations and/or changes in the assumptions underlying the report.

Recommendations issued by IPOPEMA Securities S.A. they are valid for a period of 12 months from the date of issue, unless they are updated during this period. IPOPEMA Securities S.A. updates the issued recommendations depending on the market situation and subjective analysts' assessment. In the last 12 months IPOPEMA Securities S.A. has prepared recommendations concerning the company.

The date and the time stated on the front page is the date of the publication of this document. The price used throughout the recommendation to calculate adequate ratios is the "last" price stated on the front page of this document.

- The definitions of terms used in the document include:
- NII Net interest income interest income minus interest expense.
- Net F&C Net fee and commission income fee and commission income minus fee and commission expense.
- LLP loan loss provisions an expense set aside as an allowance for bad loans.
- NPL non-performing loan loans that are in default or close to be in default.
- Cost/Income operating expenses divided by total banking revenue.
- ROE return on equity net income (or adjusted net income) divided by the average shareholders' equity.
- ROA return on assets net income (or adjusted net income) divided by the average assets.
- EBIT earnings before interests and tax.
- EBITDA earnings before interests, tax, depreciation and amortization.
- EPS earnings per share the net income (or adjusted net income divided by the number of shares outstanding.

P/E – price to earnings ratio – price divided by earnings per share.

- PEG P/E ratio divided by the annual EPS growth, usually over a certain period of time.
- CAGR compound annual growth rate.

BVPS - book value per share, the book value of the Company's equity divided by the number of shares outstanding.

P/BV – price to book value - price divided by the BVPS.

DPS - dividend per share - dividend of a given year divided by the number of shares outstanding.

DY – dividend yield – dividend of a given year divided by the current price.

DDM – dividend discount model – a fundamental method of valuation based on the assumption that the value of stock equals the sum of all discounted future dividends. FV – Fair Value, calculated based on valuation methods outlined in the document.

The author of this document has no conflict of interest with the company that is the subject of this document.

Investors should be aware that flexible part of the author's compensation may depend on general financial performance of IPOPEMA Securities S.A.



IPOPEMA Securities S.A. shall act with due diligence, honestly, fairly, professionally and in accordance with the provisions of the applicable law.

IPOPEMA Securities S.A. does not guarantee achieving the investor's investment objective, the performance of company or prospective prices referred to herein.

When applying ratings for companies following criteria are used with regards to the difference between IPOPEMA's FV and company's price at the date of recommendation:

Above 10% In between (and including) -10% and 10%	Rating	Difference between FV and price at recommendatior
In between (and including) -10% and 10%	Виу	Above 10%
	Hold	In between (and including) -10% and 10%
Below -10%	Sell	Below -10%

IPOPEMA Research - Distribution by rating category (1 October 2022 – 31 Dece	mber 2022)	
	Number	%
Buy	58	75%
Hold	3	4%
Sell	16	21%
Total	77	100%

Rating History – VIGO Photonics				
Date	Recommendation	Fair Value	Price at recommendation	Author
02.08.2019	BUY	380.0	330.0	Michał Wojciechowski
16.04.2020	BUY	480.0	384.0	Michał Wojciechowski
29.07.2020	BUY	650.0	550.0	Michał Wojciechowski
08.12.2020	BUY	660.0	550.0	Michał Wojciechowski
19.05.2021	BUY	850.0	760.0	Michał Wojciechowski
13.12.2021	BUY	750.0	682.0	Michał Wojciechowski
24.08.2022	BUY	660.0	556.0	Michał Wojciechowski
28.03.2023	HOLD	600.0	566.0	Michał Wojciechowski